US20120134969A1 - Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells - Google Patents

Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells Download PDF

Info

Publication number
US20120134969A1
US20120134969A1 US13/322,195 US201013322195A US2012134969A1 US 20120134969 A1 US20120134969 A1 US 20120134969A1 US 201013322195 A US201013322195 A US 201013322195A US 2012134969 A1 US2012134969 A1 US 2012134969A1
Authority
US
United States
Prior art keywords
crbn
cells
pharmaceutical composition
gene
cerebral cortex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/322,195
Other languages
English (en)
Inventor
Hiroshi Handa
Hideki Ando
Takumi Itoh
Kentaro Hotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Tokyo Institute of Technology NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Institute of Technology NUC filed Critical Tokyo Institute of Technology NUC
Assigned to TOKYO INSTITUTE OF TECHNOLOGY reassignment TOKYO INSTITUTE OF TECHNOLOGY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANDO, HIDEKI, HANDA, HIROSHI, HOTTA, KENTARO, ITOH, TAKUMI
Publication of US20120134969A1 publication Critical patent/US20120134969A1/en
Assigned to CELGENE CORPORATION reassignment CELGENE CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TOKYO INSTITUTE OF TECHNOLOGY
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Definitions

  • the present invention relates to a pharmaceutical composition used for treating a disease of cerebral cortex and the like, a method comprising administering the pharmaceutical composition to a non-human animal and inducing proliferation of neural stem cells or neural progenitor cells of the non-human animal and differentiation of these cells into nerve cells, and a method for screening for a therapeutic drug for a disease of cerebral cortex and the like.
  • a factor that induces differentiation into nerve cells can be newly discovered, it would enable regenerating nerve cells, and using them for treating a disease of cerebral cortex such as Alzheimer's disease.
  • the present invention was completed under the foregoing technical background with an aim to provide a novel factor that induces differentiation into nerve cells.
  • CRBN cereblon
  • CRBN is a protein that forms a ubiquitin ligase complex and its amino acid sequence is also publicly known; however, it has never been known before that CRBN functions to induce proliferation of central nervous stem cells or neural progenitor cells and differentiation of these cells into nerve cells.
  • Higgins et al. describing the relationship between CRBN and the brain (J. J. Higgins et al., (2004), Neurology, 63, 1927-1931). Higgins et al. have reported that a family lineage involving mild mental retardation is observed to bear a mutated crbn gene. However, this report does not suggest that CRBN has the aforementioned functions.
  • the present invention was accomplished based on the foregoing findings.
  • the present invention provides the following [1] to [11].
  • a pharmaceutical composition comprising 1) CRBN, 2) a nucleic acid encoding CRBN, or 3) a stem cell or a neural progenitor cell in which CRBN is expressed.
  • the pharmaceutical composition according to [1] or [2] comprising the nucleic acid encoding CRBN and a nucleic acid encoding a protein that forms a ubiquitin ligase complex with CRBN.
  • a method comprising administering the pharmaceutical composition according to any of [1] to [7] to a non-human animal and differentiating a neural stem cell or a neural progenitor cell of the non-human animal into a nerve cell.
  • a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex comprising contacting a test substance with a ubiquitin ligase complex containing CRBN and measuring a ubiquitin ligase activity of the ubiquitin ligase complex to select a test substance with an increased ubiquitin ligase activity.
  • a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex comprising culturing a neural stem cell or a neural progenitor cell in the presence of a test substance and measuring an expression level of CRBN in the neural stem cell or the neural progenitor cell to select a test substance with an increased expression level of CRBN.
  • CRBN contained in the pharmaceutical composition of the present invention induces proliferation of central nervous stem cells or neural progenitor cells and differentiation of these cells into nerve cells. Accordingly, the pharmaceutical composition of the present invention is useful as a therapeutic drug for a disease of cerebral cortex such as Alzheimer's disease. Further, CRBN is also useful as a target substance for the development of a novel therapeutic drug for a disease of cerebral cortex.
  • FIG. 1 shows fluorescence microscopic pictures of zebrafish embryos.
  • the upper left shows a normal embryo
  • the upper right shows an embryo in which the crbn gene is overexpressed
  • the lower left shows an embryo in which the lhx2 gene is knocked down
  • the lower right shows an embryo in which the lhx2 gene is knocked down while the crbn gene is overexpressed.
  • FIG. 2 shows microscopic pictures of zebrafish embryos.
  • the picture on the right shows an embryo in which the crbn gene is overexpressed and the picture on the left shows an untreated embryo. Both pictures were taken at the same magnification.
  • FIG. 3 shows microscopic pictures of zebrafish, into which crbn gene-overexpressing cells (fluorescently labeled with rhodamine) are transplanted.
  • the top pictures and the bottom pictures were taken at 200-fold magnification and 100-fold magnification, respectively.
  • the pictures on the left column are bright-field images and the pictures on the right column are fluorescent images.
  • FIG. 4 shows electrophoresis images for the detection of the ubiquitin ligase activity of a CRBN complex (FH-CRBN complex) using an in vitro reaction system.
  • the images on the left, middle, and right show ubiquitin, Cul4A, which is a CRBN complex-forming factor, and ubiquitinated CRBN, respectively, each detected by immunoblotting. Mock indicates the case of the use of a control experimental sample.
  • FIG. 5 shows an electrophoresis image for the detection of the ubiquitin ligase activity of the CRBN complex in live cells.
  • FIG. 6 shows close-up pictures of zebrafish heads in which glia cells were fluorescently stained.
  • the left part of the picture corresponds to the front end portion.
  • the picture on the left shows a normal individual and the picture on the right shows an individual with overexpressed CRBN.
  • FIG. 7 shows close-up pictures of zebrafish heads in which serotonin-producing cells were fluorescently stained. These pictures were taken from the dorsal side of the brain. The top part of the picture corresponds to the front end portion. The picture on the left shows a normal individual and the picture on the right shows an individual with overexpressed CRBN. In the Figure, numbers 1 , 2 , and 3 indicates the pineal gland, the ventral posterior tuberculum, and the raphe nucleus, respectively.
  • FIG. 8 shows pictures of zebrafish in which undifferentiated cells are transplanted into the cerebral ventricle.
  • Pictures A to D show the cases in which cells that do not express CRBN are transplanted
  • pictures E to H show the cases in which cells that express CRBN are transplanted.
  • Pictures A and E are bright-field images
  • pictures B and E are fluorescence images of Alexa Fluor (R) (indicating the distribution of tubulin)
  • pictures C and G are fluorescence images of rhodamine (indicating the distribution of donor cells)
  • pictures D and H are fluoresce images of Alexa Fluor (R) and rhodamine.
  • the pharmaceutical composition of the present invention comprises 1) CRBN, 2) a nucleic acid encoding CRBN, or 3) a stem cell or a neural progenitor cell in which CRBN is expressed.
  • CRBN is a known protein, and the base sequence of the gene encoding CRBN (crbn gene) is also published in a database.
  • the base sequences of human-derived crbn gene, mouse-derived crbn gene, rat-derived crbn gene, and zebrafish-derived crbn gene are registered in Entrez Gene under Gene ID: 51185, Gene ID: 58799, Gene ID: 297498, and Gene ID: 445491, respectively.
  • Naturally-derived CRBN and crbn gene may be used, while modified CRBN capable of forming an active ubiquitin ligase complex, being composed of an amino acid sequence resulting from deletion, substitution, or addition of one or several amino acids in the amino acid sequence of naturally-derived CRBN and a gene encoding this modified form may be used.
  • the pharmaceutical composition of the present invention may contain any of CRBN, a nucleic acid encoding CRBN, and a stem cell or a neural progenitor cell in which CRBN is expressed as an active ingredient.
  • the pharmaceutical composition containing these substances as an active ingredient can be prepared and used in a similar manner to a known drug containing a protein, a nucleic acid, a stem cell, and a progenitor cell as an active ingredient.
  • the nucleic acid encoding CRBN may be either DNA or RNA.
  • the nucleic acid is preferably inserted in an appropriate vector so that it can act on neural stem cells in the brain.
  • a vector examples include a virus vector.
  • the virus vector include an adenovirus vector, a retrovirus vector, and a lentivirus vector.
  • the stem cell in which CRBN is expressed is preferably an iPS cell derived from the patient him/her-self so as to be able to avoid rejection; however, other stem cells such as ES cells, adult stem cells, and cord blood stem cells may also be used.
  • CRBN may be expressed in stem cells, and it is preferably overexpressed.
  • a method for expressing or overexpressing CRBN can be carried out in accordance with, for example, the method of Ando et al. (Ando and Okamoto, Mar. Biotechnol. 8(3): 295-303, 2006), while it may also be carried out by other methods such as other microinjection methods, the caged RNA method (Ando et al., Nat. Genet. 28: 317-325, 2001), the electroporation method, the calcium phosphate method, the DEAE dextran method, the virus method, sonoporation method, and the transposon method.
  • the pharmaceutical composition of the present invention can be administered by injection, drip infusion, and the like into the cerebral ventricle, the skin, the intraperitoneal cavity, the vein, the artery, or the spinal marrow fluid.
  • CRBN acts on the neural stem cells or neural progenitor cells in the brain, except for the case in which it is administered into the cerebral ventricle, it is preferable to provide such a treatment that would enable passage of CRBN through the blood brain barrier.
  • a treatment methods such as binding CRBN with essential endogenous substances that are actively taken up, carrying out structural modification of CRBN so as to avoid recognition by efflux transporters, and reducing the molecular weight to such a size that contains only a minimum functional domain may be possible.
  • stem cells or neural progenitor cells are used as active ingredients, the pharmaceutical composition is directly administered into the cerebral ventricle.
  • the dose of the pharmaceutical composition of the present invention is preferably administered in an amount of approximately 0.5 mg to 100 mg; when a nucleic acid encoding CRBN is administered, it is preferably administered in an amount of approximately 1 mg to 200 mg; and when a stem cell or a neural progenitor cell in which CRBN is expressed is administered, preferably 500 cells to 5000 cells are administered in a volume of approximately 50 ⁇ l to 500 ⁇ l.
  • the injection fluid and the drip infusion fluid may contain components that are normally contained in these solutions.
  • a component include a liquid carrier (such as potassium phosphate buffer, physiological saline, Ringer's solution, distilled water, polyethylene glycol, plant oil and fat, ethanol, glycerin, dimethyl sulfoxide, and polypropylene glycol), antimicrobial agents, local anesthetics (such as procaine hydrochloride and dibucaine hydrochloride), buffer (such as tris-HCl buffer and hepes buffer), and osmotic pressure regulators (such as glucose, sorbitol, and sodium chloride).
  • a liquid carrier such as potassium phosphate buffer, physiological saline, Ringer's solution, distilled water, polyethylene glycol, plant oil and fat, ethanol, glycerin, dimethyl sulfoxide, and polypropylene glycol
  • antimicrobial agents such as procaine hydrochloride and dibucaine hydrochloride
  • buffer
  • the pharmaceutical composition of the present invention may contain: 1) in addition to CRBN, a protein that forms a ubiquitin ligase complex with CRBN, 2) in addition to a nucleic acid encoding CRBN, a nucleic acid encoding a protein that forms a ubiquitin ligase complex with CRBN, and 3) in addition to CRBN, a stem cell or a neural progenitor cell in which a protein that forms a ubiquitin ligase complex with CRBN are expressed.
  • Examples of the protein that forms a ubiquitin ligase complex with CRBN include DDB1 (Damaged DNA Binding protein), Cul4A (Cullin 4A), Cul4B (Cullin 4B), and Rod (RBX1).
  • DDB1 Damaged DNA Binding protein
  • Cul4A Cullin 4A
  • Cul4B Cullin 4B
  • Rod RBX1
  • these proteins are known proteins, and the base sequences of the genes encoding these proteins (i.e., ddb1 gene, cul4a gene, cul4b gene, and roc1 gene) are also published in a database.
  • the base sequences of human-derived ddb1 gene, mouse-derived ddb1 gene, rat-derived ddb1 gene, and zebrafish-derived ddb1 gene are registered in Entrez Gene under Gene ID: 1642, Gene ID: 13194, Gene ID: 64470, and Gene ID: 393599, respectively;
  • the base sequences of human-derived cul4a gene, mouse-derived cul4a gene, rat-derived cul4a gene, and zebrafish-derived cul4a gene are registered in Entrez Gene under Gene ID: 8451, Gene ID: 99375, Gene ID: 361181, and Gene ID: 394002, respectively;
  • the base sequences of human-derived cul4b gene, mouse-derived cul4b gene, rat-derived cul4b gene, and zebrafish-derived cul4b gene are registered in Entrez Gene under Gene ID: 8450, Gene ID: 72584, Gene ID: 302502, and Gene ID: 560313, respectively; and the base sequence
  • Each of these proteins and genes may be naturally-derived one, while a modified protein capable of forming an active ubiquitin ligase complex, being composed of an amino acid sequence resulting from deletion, substitution, or addition of one or several amino acids in the amino acid sequence of a naturally-derived protein and a gene encoding this modified protein may be used.
  • the ubiquitin ligase complex contains, in addition to CRBN, three kinds of proteins, which are DDB1, CuL4A, and Roc1, or DDB1, CuL4B, and Roc1.
  • the pharmaceutical composition of the present invention preferably contains (or expresses) all these three kinds of proteins (or nucleic acids encoding these proteins), it may contain only one or some of them.
  • the pharmaceutical composition of the present invention can be used for the treatment of a disease of cerebral cortex or a surgical injury of cerebral cortex, or for regenerating cerebral cortex.
  • diseases of cerebral cortex include Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jakob disease, Huntington's disease, progressive supranuclear palsy, and corticobasal degeneration.
  • the pharmaceutical composition of the present invention is intended to be used for humans, it may be administered to an animal other than humans to induce proliferation of the neural stem cells or neural progenitor cells or differentiation of these cells into nerve cells in these animals.
  • the target animals are mainly vertebrates, and examples thereof include mice, rats, monkeys, dogs, ferrets, hamsters, chickens, xenopus, zebrafish, and medaka.
  • CRBN CRBN induces proliferation of neural stem cells or neural progenitor cells and differentiation of these cells into nerve cells, as described in Examples. However, 70 to 80% of the genome synteny is conserved between humans and zebrafish (Nature Reviews Genetics 8, 353-367 (May 2007)). Accordingly, it is predicted that CRBN exhibits similar effects as those confirmed in zebrafish also in other vertebrates including humans.
  • the protein can be used for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex. This is specifically exemplified by the following methods (A) and (B).
  • a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex comprising the steps of contacting a test substance with a ubiquitin ligase complex containing CRBN and measuring a ubiquitin ligase activity of the ubiquitin ligase complex to select a test substance with an increased ubiquitin ligase activity.
  • a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex comprising the steps of culturing a neural stem cell or a neural progenitor cell in the presence of a test substance and measuring an expression level of CRBN in the neural stem cell or the neural progenitor cell to select a test substance with an increased expression level of CRBN.
  • the ubiquitin ligase activity can be measured in accordance with, for example, the method of Angers et al. (Nature, 443, 590-593, 2006) and the method of Groisman et al. (Cell, 113, 357-367, 2003).
  • whether or not the test substance has increased the ubiquitin ligase activity can be judged by measuring the ubiquitin ligase activity of a ubiquitin ligase complex containing CRBN without contacting with the test substance and making a comparison with the value thus obtained.
  • the substance thus selected by the method (A) acts to increase the ubiquitin ligase activity of the CRBN-containing ubiquitin ligase complex present in neural stem cells or neural progenitor cells in the living body. It is speculated that proliferation of neural stem cells or neural progenitor cells and differentiation of these cells into nerve cells effected by CRBN are mediated by the ubiquitin ligase activity possessed by this complex. Accordingly, it is assumed that the substance that is selected by the method (A) facilitates proliferation of neural stem cells or neural progenitor cells and differentiation of these cells into nerve cells effected by CRBN, and thus is therapeutically effective for a disease of cerebral cortex and a surgical injury of cerebral cortex.
  • neural stem cells to be used basically cells such as ES cells, iPS cells, and adult stem cells that are subjected to neuronal differentiation induction are employed. Further, neural stem cells such as ones derived from the subventricular zone of adult mice or the hippocampus of adult rats may also be used.
  • a method for measuring the expression level of CRBN can be carried out by, for example, a method using an antibody against CRBN, in situ hybridization method, the RT-PCR method, and Northern blotting method.
  • whether or not the test substance has increased the expression level of CRBN can be judged by culturing neural stem cells or neural progenitor cells in the absence of the test substance and measuring the expression level of CRBN, and then making a comparison with the value thus obtained.
  • the substance that is selected by the method (B) acts to increase the expression level of CRBN in neural stem cells or neural progenitor cells in the living body. Accordingly, it is assumed that the substance that is selected by the method (B) facilitates proliferation of neural stem cells or neural progenitor cells and differentiation of these cells into nerve cells effected by CRBN, and thus is therapeutically effective for a disease of cerebral cortex and a surgical injury of cerebral cortex.
  • the expression of all the genes except the lhx2 gene i.e., the crbn gene, the six3.2 gene, and a gene encoding a protein composing an E3 ubiquitin ligase complex with crbn
  • this method was used to obtain the first data.
  • RNA lipofection into the prospective head region of the embryo was carried out.
  • the method of lipofection was entirely in accordance with the technique developed and published by Ando et al. (Ando and Okamoto, Efficient transfection strategy for the spatiotemporal control of gene expression in zebrafish. Mar. Biotechnol. 8(3): 295-303, 2006).
  • AMO antisense morpholino oligonucleotide
  • the basic principle is as follows: embryos in which one (A) of the two kinds of genes suggested to have a functional association is knocked down by the method described in (3) above are cultured up to six hours after fertilization (gastrula stage), and in the prospective forebrain region of the embryos, the expression of the other gene (B) is induced by the in vivo lipofection method described in (2) above.
  • A embryos in which one (A) of the two kinds of genes suggested to have a functional association is knocked down by the method described in (3) above are cultured up to six hours after fertilization (gastrula stage), and in the prospective forebrain region of the embryos, the expression of the other gene (B) is induced by the in vivo lipofection method described in (2) above.
  • Antibody staining of early neurons of zebrafish was performed by the following technique. The embryos 24 to 28 hours after fertilization were fixed at 4° C. for 12 hours in a 4% paraformaldehyde/phosphate buffer (pH 8.0). After washing four times with phosphate buffer, where each wash was performed for 15 minutes, blocking was carried out at normal temperature for one hour in a 5% newborn goat serum dissolved in 0.5% Triton X-100/phosphate buffer. Primary antibody reaction was carried out using a monoclonal anti-acetylated tubulin antibody diluted at 1:1000 in the same solution at 4° C. for 12 hours.
  • CRBN and a binding protein (referred to as a CRBN complex) were purified from a cell lysate solution of mammalian cells expressing CRBN fused with a FLAG epitope tag using M2 FLAG agarose beads (SIGMA). Subsequently, the CRBN complex thus purified was mixed with an aqueous solution containing Uba1 (E1), UbcH5b (E2), and a recombinant GST fusion ubiquitin (Ub) protein, and after addition of ATP, the mixture was left to stand at 30 to 37° C. for two hours.
  • E1 Uba1
  • E2 UbcH5b
  • Ub recombinant GST fusion ubiquitin
  • reaction was terminated by SDS, and self-ubiquitination and ubiquitination of the binding protein were visualized by polyacrylamide gel electrophoresis and immunoblotting, whereby the ubiquitin ligase activity was detected and measured.
  • This process was carried out basically in accordance with the method of Ohtake et al. MG132, which is a proteasome inhibitor, was applied to mammalian cells expressing CRBN fused with a FLAG epitope tag, and the cells were left still. Subsequently, the cells were disrupted, and from the resulting cell lysate solution, FLAG was purified and CRBN was extracted, and then immunoblotting was performed under similar, but stricter, conditions to the above, whereby the self-ubiquitination was detected and measured.
  • zebrafish Two-day-old zebrafish were used (for glia cell staining and serotonin-producing cell staining, zebrafish 56 hours and 49 hours after fertilization were used, respectively). Zebrafish were fixed with 4% paraformaldehyde (PFA) and then washed with phosphate buffer (PBS), followed by treatment with 10 ⁇ g/ml protease K for partial digestion of the epidermis. After the digestion reaction, the zebrafish were washed with PEST (PBS+0.5% Triton X-100) for 20 minutes and then fixed with PFA again. The fixed zebrafish were washed with PBST at room temperature for one hour, followed by blocking using PBST+5% goat serum.
  • PFA paraformaldehyde
  • PBS phosphate buffer
  • protease K protease K
  • the resulting specimens were reacted with a monoclonal anti-glia antibody (zrf-1/zrf-2) or a rabbit anti-serotonin antibody at 4° C. overnight (12 to 18 hours). Subsequently, the specimens were washed with PBST+5% goat serum for one hour at room temperature, and secondary antibody reaction was carried out by substituting the antibody for a goat anti-mouse IgG antibody (Cy-2 conjugate for glia cell staining) or a goat anti-rabbit IgG antibody (Cy-5 conjugate for serotonin-producing cell staining) at 4° C. overnight (12 to 18 hours). Subsequently, the specimens were washed with PBST at room temperature for one hour.
  • PBST was replaced by 30%, 50%, 70% glycerol/PBS and the whole zebrafish were mounted on glass slides to obtain preparations. Fluorescence was observed under excitation wavelength of Cy-2 and Cy-5 and the distribution of the glia cells or the serotonin-producing cells was recorded. It is to be noted that glia cells were observed from the lateral side of zebrafish, while the serotonin-producing cells were photographed from the dorsal side in order to observe the distribution of the cells along the midline.
  • a mixed solution of CRBN-coding RNA (700 ng/ ⁇ l) and 2% rhodamine dextran was injected into the zebrafish embryos at the 1-cell stage immediately after fertilization.
  • the embryos were cultured up to four hours after fertilization and 10 to 20 cells were collected by a suction capillary, which were injected into the diencephalic ventricle of embryos 30 hours after fertilization, whereby the cells were transplanted.
  • Zebrafish having undergone transplantation were reared up to three days after fertilization in zebrafish physiological saline (E3 Ringer) and then fixed with 4% paraformaldehyde.
  • primary antibody reaction and secondary antibody reaction were carried out using a monoclonal anti-acetylated tubulin antibody and an anti-mouse IgG antibody conjugated with Alexa Fluor (R) (excited at 488 nm), respectively. Then, while observing the fluorescently-labeled nerve cell axon, distribution of the transplanted cells labeled with rhodamine dextran (excited at 543 nm) was studied.
  • FIG. 1 Compared to the normal embryo ( FIG. 1 , upper left panel), brain shrinkage was observed in the lhx2 gene-knockdown embryo ( FIG. 1 , lower left panel). Meanwhile, similarly to the crbn gene-overexpressing embryo ( FIG. 1 , upper right panel), brain enlargement was observed in the embryo in which lhx2 gene was knocked down while crbn gene was overexpressed ( FIG. 1 , lower right panel). From this observation, it is considered that CRBN functions downstream of Lhx2, directly inducing proliferation of central nervous stem cells and differentiation of these cells into nerve cells.
  • mRNA encoding CRBN and a fluorescent substance were injected together into donor embryos so that CRBN was overexpressed.
  • the resulting blastula was transplanted into another individual and differentiation of donor-derived cells distributed in the cerebral ventricle was observed under a fluorescent microscope.
  • the transplanted donor-derived cells were significantly differentiated into the olfactory bulb, which is the telencephalon tissue of fish ( FIG. 3 , arrowhead).
  • CRBN-expressing cells were distributed into the cerebral ventricle, they differentiated into neural stem cells and migrated along a cell migration pathway called Rostral Migratory Stream (RMS) and differentiated into the brain tissue in the dorsal telencephalon, where the cerebral cortex develops in mammals.
  • RMS Rostral Migratory Stream
  • CRBN acts to proliferate and differentiate cells, while normally recognizing the spatial pattern of the brain.
  • the present invention is useful as a therapeutic drug for a disease of cerebral cortex such as Alzheimer's disease. Further, it is also useful for the development of a novel therapeutic drug for a disease of cerebral cortex.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Food Science & Technology (AREA)
US13/322,195 2009-05-25 2010-05-24 Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells Abandoned US20120134969A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009124811 2009-05-25
JP2009-124811 2009-05-25
PCT/JP2010/058722 WO2010137547A1 (ja) 2009-05-25 2010-05-24 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/058722 A-371-Of-International WO2010137547A1 (ja) 2009-05-25 2010-05-24 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/629,452 Division US9611465B2 (en) 2009-05-25 2015-02-23 Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell

Publications (1)

Publication Number Publication Date
US20120134969A1 true US20120134969A1 (en) 2012-05-31

Family

ID=43222656

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/322,195 Abandoned US20120134969A1 (en) 2009-05-25 2010-05-24 Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
US14/629,452 Active US9611465B2 (en) 2009-05-25 2015-02-23 Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/629,452 Active US9611465B2 (en) 2009-05-25 2015-02-23 Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell

Country Status (5)

Country Link
US (2) US20120134969A1 (ja)
EP (1) EP2436387B1 (ja)
JP (1) JP5645816B2 (ja)
CN (1) CN102448472A (ja)
WO (1) WO2010137547A1 (ja)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014123267A1 (ko) * 2013-02-07 2014-08-14 광주과학기술원 Crbn ko 마우스의 제조방법 및 이의 용도
WO2015127351A1 (en) * 2014-02-24 2015-08-27 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
US9365640B2 (en) 2011-04-29 2016-06-14 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
US9611465B2 (en) 2009-05-25 2017-04-04 Celgene Corporation Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell
US9857359B2 (en) 2012-06-29 2018-01-02 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
US10092555B2 (en) 2014-06-27 2018-10-09 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
CN111830000A (zh) * 2020-07-23 2020-10-27 南开大学 一种对纳米颗粒加载探针作用于斑马鱼胚胎/幼鱼的方法
US10816544B2 (en) 2017-02-03 2020-10-27 Celgene Corporation Methods for measuring small molecule affinity to cereblon
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
US11963520B2 (en) 2016-01-19 2024-04-23 Celgene Corporation Transgenic mouse expressing human cereblon

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013010153A (es) 2011-03-11 2013-09-26 Celgene Corp Metodos de tratamiento del cancer utilizado 3 - (5 - amino- 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il) - piperidin - 2, 6 - diona.
EP2683412B1 (en) 2011-03-11 2017-05-03 Mayo Foundation For Medical Education And Research Methods for assessing responsiveness of cancer cells to lenalidomide, thalidomide, and/or pomalidomide
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
CN108245518B (zh) 2012-08-09 2021-08-31 细胞基因公司 利用3-(4-((4-(吗啉代甲基)苯甲基)氧基)-1-氧代异二氢吲哚-2-基)哌啶-2,6- 二酮治疗癌症的方法
JP6382949B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
TW201534305A (zh) 2013-05-03 2015-09-16 Celgene Corp 使用組合療法治療癌症之方法
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
WO2015077058A2 (en) * 2013-11-08 2015-05-28 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
EA201691144A1 (ru) 2013-12-06 2016-11-30 Селджин Корпорейшн Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459613B2 (en) 2015-09-11 2022-10-04 The Brigham And Women's Hospital, Inc. Methods of characterizing resistance to modulators of Cereblon
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP2020513248A (ja) 2016-10-19 2020-05-14 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響による親和性細胞抽出
NZ754020A (en) * 2016-11-25 2022-11-25 Genuv Inc Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
US20210040166A1 (en) * 2017-10-31 2021-02-11 The General Hospital Corporation Molecular switch-mediated control of engineered cells
CA3085784A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer driver and controller

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015194A1 (en) * 2005-07-12 2007-01-18 Mordechai Shohat Methods and kits for diagnosing and treating mental retardation

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP1134293A3 (en) 1992-03-04 2004-01-07 The Regents of The University of California Comparative genomic hybridization (CGH)
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US8143283B1 (en) 1993-03-01 2012-03-27 The Children's Medical Center Corporation Methods for treating blood-born tumors with thalidomide
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5573758A (en) * 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
ES2339425T3 (es) 1996-07-24 2010-05-20 Celgene Corporation 2-(2,6-dioxopiperidin-3-il)-ftalimidas y -1-oxoisoindolinas sustituidas y procedimiento para reducir los niveles de tnf-alfa.
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
EP1361210B1 (en) 1996-08-12 2008-12-24 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
CZ299253B6 (cs) 1998-03-16 2008-05-28 Celgene Corporation Isoindolinový derivát, jeho použití pro výrobu léciva a farmaceutická kompozice tento derivát obsahující
US6927024B2 (en) 1998-11-30 2005-08-09 Genentech, Inc. PCR assay
CZ20013338A3 (cs) 1999-03-18 2002-03-13 Celgene Corporation Substituované 1-oxo-a l,3-dioxoisoindoliny a jejich pouľití ve farmaceutických prostředcích pro sníľení koncentrací zánětlivých cytokinů
US7186507B2 (en) 1999-12-09 2007-03-06 Indiana University Research And Technology Corporation Fluorescent in situ RT-PCR
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
AU2002247248B2 (en) 2001-03-02 2007-07-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education PCR method
JP2002315576A (ja) 2001-04-23 2002-10-29 Inst Of Physical & Chemical Res 遺伝子発現調節方法
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP2005537257A (ja) 2002-07-08 2005-12-08 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン結合部位
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US7122799B2 (en) 2003-12-18 2006-10-17 Palo Alto Research Center Incorporated LED or laser enabled real-time PCR system and spectrophotometer
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
CN101111234A (zh) 2004-12-01 2008-01-23 细胞基因公司 包含免疫调节化合物的组合物及其治疗免疫缺陷疾病的用途
US20080051379A1 (en) 2004-12-01 2008-02-28 Trustees Of Boston University Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
AU2006208201A1 (en) 2005-01-25 2006-08-03 Celgene Corporation Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
US7504225B2 (en) 2005-05-12 2009-03-17 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
RU2008112221A (ru) 2005-08-31 2009-10-10 Селджин Корпорейшн (Us) Соединения ряда изоиндолимидов, их композиции и способы применения
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20070128636A1 (en) 2005-12-05 2007-06-07 Baker Joffre B Predictors Of Patient Response To Treatment With EGFR Inhibitors
US7892740B2 (en) 2006-01-19 2011-02-22 The University Of Chicago Prognosis and therapy predictive markers and methods of use
WO2007108968A2 (en) * 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US20100284915A1 (en) 2006-06-30 2010-11-11 Hongyue Dai Genes associated with chemotherapy response and uses thereof
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
JP5388854B2 (ja) 2006-09-26 2014-01-15 セルジーン コーポレイション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
US20080280779A1 (en) 2006-09-26 2008-11-13 Shaughnessy Jr John D Gene expression profiling based identification of genomic signatures of multiple myeloma and uses thereof
WO2009075797A2 (en) 2007-12-07 2009-06-18 Celgene Corporation Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma
US20100021437A1 (en) 2008-04-07 2010-01-28 The McLean Hospital Corporation Whitehead Institute for Biomedical Research Neural stem cells derived from induced pluripotent stem cells
WO2009144699A1 (en) 2008-05-26 2009-12-03 Yeda Research And Development Co. Ltd. Methods of treating cancer of the central nervous system
WO2010017515A2 (en) 2008-08-08 2010-02-11 Integrated Diagnostics Inc. Breast cancer specific markers and methods of use
AU2010236606A1 (en) 2009-04-14 2011-11-03 Merck Sharp & Dohme Corp. Interferon-alfa sensitivity biomarkers
JP5645816B2 (ja) 2009-05-25 2014-12-24 国立大学法人東京工業大学 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
JP5660578B2 (ja) 2009-10-20 2015-01-28 国立大学法人東京工業大学 サリドマイド標的因子を利用したスクリーニング方法
PT3202461T (pt) 2010-02-11 2019-03-19 Celgene Corp Derivados arilmetoxi-indolina e composições que os compreendem e métodos para a sua utilização
CA2792872A1 (en) 2010-03-12 2011-09-15 Celgene Corporation Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
US9670547B2 (en) 2010-09-15 2017-06-06 Almac Diagnostics Limited Molecular diagnostic test for cancer
MX2013010153A (es) 2011-03-11 2013-09-26 Celgene Corp Metodos de tratamiento del cancer utilizado 3 - (5 - amino- 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il) - piperidin - 2, 6 - diona.
EP2683412B1 (en) 2011-03-11 2017-05-03 Mayo Foundation For Medical Education And Research Methods for assessing responsiveness of cancer cells to lenalidomide, thalidomide, and/or pomalidomide
HUE037955T2 (hu) 2011-03-11 2018-09-28 Celgene Corp A 3-(5-amino-2-metil-4-oxo-4H-kinazolin-3-il)- piperidin-2,6-dion szilárd halmazállapotú formái, valamint gyógyászati készítményei és felhasználása
CN103688176A (zh) 2011-04-29 2014-03-26 细胞基因公司 利用cereblon作为预报因子治疗癌和炎性疾病的方法
CA2835179A1 (en) 2011-05-06 2012-11-15 Xentech Markers for cancer prognosis and therapy and methods of use
MX358517B (es) 2012-06-29 2018-08-24 Celgene Corp Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon.
CN108245518B (zh) 2012-08-09 2021-08-31 细胞基因公司 利用3-(4-((4-(吗啉代甲基)苯甲基)氧基)-1-氧代异二氢吲哚-2-基)哌啶-2,6- 二酮治疗癌症的方法
WO2014028445A2 (en) 2012-08-14 2014-02-20 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015194A1 (en) * 2005-07-12 2007-01-18 Mordechai Shohat Methods and kits for diagnosing and treating mental retardation

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
Ando et al." Efficient transfection strategy for the spatiotemporal control of gene expression in zebrafish." Mar Biotechnol (NY). 2006 May-Jun;8(3):295-303. Epub 2006 Apr 18. *
Babin et al. "Zebrafish models of human motor neuron diseases: Advantages and limitations." Progress in Neurobiology(2014); 118: Pgs. 36-58. *
Bartlett "Fenner Conference: Regulation of neural stem cell differentiation in the forebrain." Immunology and Cell Biology 76, 414-418 (1998). *
Bartlett "Fenner Conference: Regulation of neural stem cell differentiation in the forebrain." Immunology and Cell Biology(1998); 76: Pgs. 414-418. *
Bisht et al. "Brain Drug Delivery System: A Comprehensive review on recent experimental and clinical findings."IJPSR( 2011); 2(4): Pgs.792-806. *
Higgins et al. "A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation" Neurology. 63(10): 1927-1931.(2004). *
Hsich et al. " Review: Critical Issues in Gene Therapy for Neurologic Disease." Human Gene Therapy (2002) 13: Pgs.579-604 *
Hsich et al. " Review: Critical Issues in Gene Therapy for Neurologic Disease." Human Gene Therapy 13:579-604 (2002). *
Ito et al. "Identification of a Primary Target of Thalidomide Teratogenicity." Science 327, 1345 -1350 (2010). *
Ito et al. Supplemental. "Identification of a Primary Target of Thalidomide Teratogenicity." Science 327, 1-28 (2010). *
Jakobsson et al. "Lentiviral Vectors for Use in the Central Nervous System." Molecular Therapy.(2006); 13( 3):Pgs. 484-493. *
Kobayashi et al. "Overexpression of the forebrain-specific homeobox gene six3 induces rostral forebrain enlargement in zebrafish." Development. (1998);125: Pgs. 2973-2982. *
Mochida et al. "Genetic Basis of Developmental Malformations of the Cerebral Cortex" Arch Neurol. 61:637-640 (2004). *
Nakamura et al. "Freud-1/Aki1, a Novel PDK1-Interacting Protein, Functions as a Scaffold To Activate the PDK1/Akt Pathway in Epidermal Growth Factor Signaling." Molecular and Cellular Biology, 28(19): 5996-6009 (2008). *
Neve et al. "Gene Delivery Into the Brain Using Viral Vectors." Chatper 20 of Gene Delivery into the Brain Using Viral Vectors (2002). *
Razek et al. "Disorders of Cortical Formation: MR Imaging Features" AJNR Am J Neuroradiol (2009); 30: Pgs. 4-11. *
Santana et al. "Can zebrafish be used as animal model to study Alzheimer's disease?." Am J Neurodegener Dis (2012);1(1):Pgs. 32-48. *
Science Daily (http://www.sciencedaily.com/releases/2011/08/110823180459.htm) *
Science Daily (http://www.sciencedaily.com/releases/2011/08/110823180459.htm). *
Shestopalov et al. "Oligonucleotide-based tools for studying zebrafish development." Zebrafish. (2010 ); 7(1):Pgs. 31-40. *
Suzuki et al."Stabe Transgene Expression From HSV Amplicon ectors in the Brain: Potential Involvement of Immunoregulatory Signals." Molecular Therapy.(2008);16(10): Pgs. 1727-1736. *
Thomas et al. "Progress and Problems With the Use of Viral Vectors for Gene." Nat Rev Genet. (2003);4(5):Pgs.346-58. *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9611465B2 (en) 2009-05-25 2017-04-04 Celgene Corporation Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell
US9365640B2 (en) 2011-04-29 2016-06-14 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
US10047151B2 (en) 2011-04-29 2018-08-14 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
US9857359B2 (en) 2012-06-29 2018-01-02 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
WO2014123267A1 (ko) * 2013-02-07 2014-08-14 광주과학기술원 Crbn ko 마우스의 제조방법 및 이의 용도
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
WO2015127351A1 (en) * 2014-02-24 2015-08-27 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
US20170007645A1 (en) * 2014-02-24 2017-01-12 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
EP3450571A1 (en) 2014-02-24 2019-03-06 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
US10092555B2 (en) 2014-06-27 2018-10-09 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
US10668057B2 (en) 2014-06-27 2020-06-02 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
US11419861B2 (en) 2014-06-27 2022-08-23 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
US11733233B2 (en) 2015-12-28 2023-08-22 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
US11963520B2 (en) 2016-01-19 2024-04-23 Celgene Corporation Transgenic mouse expressing human cereblon
US10816544B2 (en) 2017-02-03 2020-10-27 Celgene Corporation Methods for measuring small molecule affinity to cereblon
US11644461B2 (en) 2017-02-03 2023-05-09 Celgene Corporation Methods for measuring small molecule affinity to cereblon
CN111830000A (zh) * 2020-07-23 2020-10-27 南开大学 一种对纳米颗粒加载探针作用于斑马鱼胚胎/幼鱼的方法

Also Published As

Publication number Publication date
CN102448472A (zh) 2012-05-09
EP2436387A1 (en) 2012-04-04
EP2436387A4 (en) 2013-07-17
EP2436387B1 (en) 2018-07-25
WO2010137547A1 (ja) 2010-12-02
JP5645816B2 (ja) 2014-12-24
US9611465B2 (en) 2017-04-04
US20150232826A1 (en) 2015-08-20
JPWO2010137547A1 (ja) 2012-11-15

Similar Documents

Publication Publication Date Title
US9611465B2 (en) Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell
Kline-Smith et al. The microtubule-destabilizing kinesin XKCM1 regulates microtubule dynamic instability in cells
Apel et al. Syne-1, a dystrophin-and Klarsicht-related protein associated with synaptic nuclei at the neuromuscular junction
Pan et al. Tau accelerates α-synuclein aggregation and spreading in Parkinson’s disease
Krus et al. Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy
Zappala et al. Expression of pannexin1 in the CNS of adult mouse: cellular localization and effect of 4-aminopyridine-induced seizures
EP3289090B1 (en) Promoter for the specific expression of genes in müller cells
US10179917B2 (en) Muller cell-specific promoter
EP2321417B1 (en) Stxbp1 as psychiatric biomarker in murine model system and its uses
CN109476716A (zh) 治疗线粒体障碍的方法
Elbaz et al. Reduced synaptic density and deficient locomotor response in neuronal activity‐regulated pentraxin 2a mutant zebrafish
Hagiwara et al. Developmental expression of dystrophin on the plasma membrane of rat muscle cells
US8524228B2 (en) Netrin-1 compositions and methods of use thereof
Grigorev et al. Immunohistochemical studies of cell organization in the human epiphysis
CN110317814A (zh) β-淀粉样蛋白环状核糖核酸、多肽及其应用
US20190192698A1 (en) A method for obtaining indicator signals from a cell
Korff et al. A murine model of hnRNPH2-related neurodevelopmental disorder recapitulates clinical features of human disease and reveals a mechanism for genetic compensation of HNRNPH2
Thomasen et al. SorCS2 binds progranulin to regulate motor neuron development
KR102296075B1 (ko) epcam 유전자 변이 제브라피쉬 및 이의 용도
Aït-Ali et al. The Emergence of the Metabolic Signaling of the Nucleoredoxin-like Genes during Evolution
MX2012003773A (es) Genes. metodos y composiciones relacionadas con la neurogenesis y su modulacion.
Gurdita Investigating the Mechanisms That Regulate Rod Photoreceptor Positioning and Connectivity in the Developing Murine Retina
Wang et al. Deficiency of FRMD5 results in neurodevelopmental dysfunction and autistic-like behavior in mice
KR20170071677A (ko) Ｄｇａｔ２ 돌연변이 유전자가 도입된 제브라피쉬 모델 및 이의 용도
Xue et al. Hippocampus Insulin Receptors Regulate Episodic and Spatial Memory Through Excitatory/Inhibitory Balance

Legal Events

Date Code Title Description
AS Assignment

Owner name: TOKYO INSTITUTE OF TECHNOLOGY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HANDA, HIROSHI;ANDO, HIDEKI;ITOH, TAKUMI;AND OTHERS;REEL/FRAME:027276/0531

Effective date: 20111018

AS Assignment

Owner name: CELGENE CORPORATION, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TOKYO INSTITUTE OF TECHNOLOGY;REEL/FRAME:031863/0488

Effective date: 20130926

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION